Evidence map›Paper›PMID 23649091›Full record

Trial reportInfection and immunity2013

Human leukocyte antigens and cellular immune responses to anthrax vaccine adsorbed.

Inna G Ovsyannikova, V Shane Pankratz, Robert A Vierkant, Nicholas M Pajewski, Conrad P Quinn, Richard A Kaslow, Robert M Jacobson, Gregory A Poland

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Infection and immunity, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Current Challenges in Vaccinology.Frontiers in immunology · 2020
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Inna G OvsyannikovaMayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, USA.
V Shane Pankratz
Robert A Vierkant
Nicholas M Pajewski
Conrad P Quinn
Richard A Kaslow
Robert M Jacobson
Gregory A Poland
Mayo Clinic in Florida · USCenters for Disease Control and Prevention · USMayo Clinic · USUniversity of Alabama at Birmingham · USWake Forest University · USWinnMed · US

Funding

POPULATION GENETICS ANALYSIS PROGRAM IMMUNITY TO VACCINES/INFECTION-266040068N01AI040068 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KASLOW, RICHARD ALAN · 2006 to 2006
–
NIAID NIH HHS N01 AI040068NIAID NIH HHS N01-AI40068 FROM
6 · The paper itself

Abstract

Interindividual variations in vaccine-induced immune responses are in part due to host genetic polymorphisms in the human leukocyte antigen (HLA) and other gene families. This study examined associations between HLA genotypes, haplotypes, and homozygosity and protective antigen (PA)-specific cellular immune responses in healthy subjects following immunization with Anthrax Vaccine Adsorbed (AVA). While limited associations were observed between individual HLA alleles or haplotypes and variable lymphocyte proliferative (LP) responses to AVA, analyses of homozygosity supported the hypothesis of a "heterozygote advantage." Individuals who were homozygous for any HLA locus demonstrated significantly lower PA-specific LP than subjects who were heterozygous at all eight loci (median stimulation indices [SI], 1.84 versus 2.95, P = 0.009). Similarly, we found that class I (HLA-A) and class II (HLA-DQA1 and HLA-DQB1) homozygosity was significantly associated with an overall decrease in LP compared with heterozygosity at those three loci. Specifically, individuals who were homozygous at these loci had significantly lower PA-specific LP than subjects heterozygous for HLA-A (median SI, 1.48 versus 2.13, P = 0.005), HLA-DQA1 (median SI, 1.75 versus 2.11, P = 0.007), and HLA-DQB1 (median SI, 1.48 versus 2.13, P = 0.002) loci, respectively. Finally, homozygosity at an increasing number (≥ 4) of HLA loci was significantly correlated with a reduction in LP response (P < 0.001) in a dose-dependent manner. Additional studies are needed to reproduce these findings and determine whether HLA-heterozygous individuals generate stronger cellular immune response to other virulence factors (Bacillus anthracis LF and EF) than HLA-homozygous subjects.

Indexed as

Immunity, CellularAdolescentAdultAllelesAnthraxAnthrax VaccinesAntibody FormationBacillus anthracisCell ProliferationDose-Response Relationship, DrugDouble-Blind MethodFemaleGenetic LociHaplotypesHeterozygoteHistocompatibility TestingAnthrax VaccinesHLA-A AntigensHLA-DQA1 antigenHLA-DQ alpha-ChainsHLA-DQB1 antigenHLA-DQ beta-Chains

Identifiers

PMID23649091
PMCPMC3697592
OpenAlexW2109692396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.